Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.

@article{Ortiz2016IntegratingGI,
  title={Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.},
  author={Michael V Ortiz and Rachel Kobos and Michael F. Walsh and Emily K. Slotkin and Stephen S. Roberts and Michael F. Berger and Meera R. Hameed and David B. Solit and Marc Ladanyi and Neerav N Shukla and Alex Kentsis},
  journal={Pediatric blood & cancer},
  year={2016},
  volume={63 8},
  pages={1368-74}
}
BACKGROUND Pediatric oncologists have begun to leverage tumor genetic profiling to match patients with targeted therapies. At the Memorial Sloan Kettering Cancer Center (MSKCC), we developed the Pediatric Molecular Tumor Board (PMTB) to track, integrate, and interpret clinical genomic profiling and potential targeted therapeutic recommendations. PROCEDURE This retrospective case series includes all patients reviewed by the MSKCC PMTB from July 2014 to June 2015. Cases were submitted by… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 34 references

CC-BY 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint

  • A. Schramm, J. Koster, +22 authors H.N.S. Lee
  • bioRxiv preprint first posted online Feb
  • 2016
1 Excerpt

Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence

  • J. Howick, I. Chalmers, +6 authors H. Thornton
  • Oxford Centre
  • 2016
2 Excerpts

Kvistborg, Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy

  • S. Kelderman, T. N. Schumacher
  • Cancer Cell,
  • 2015
1 Excerpt

Sharfman, Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors

  • L. A. Fecher, W.H
  • Biologics,
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…